Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) insider Carlos Nueno sold 29,432 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $9.20, for a total transaction of $270,774.40. Following the completion of the transaction, the insider owned 35,312 shares of the company’s stock, valued at approximately $324,870.40. This trade represents a 45.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Teladoc Health Price Performance
TDOC opened at $9.01 on Tuesday. The company’s 50 day moving average price is $6.56 and its two-hundred day moving average price is $6.55. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -10.47 and a beta of 2.00. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.89.
Teladoc Health (NYSE:TDOC – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The company had revenue of $605.10 million for the quarter, compared to analyst estimates of $588.14 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share. Teladoc Health’s revenue was down 3.4% compared to the same quarter last year. As a group, equities research analysts predict that Teladoc Health, Inc. will post -0.86 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in Teladoc Health by 1.3% in the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after purchasing an additional 107,400 shares during the period. Pale Fire Capital SE increased its stake in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after purchasing an additional 1,454,288 shares in the last quarter. Monaco Asset Management SAM acquired a new position in shares of Teladoc Health during the second quarter valued at about $26,864,000. Quantinno Capital Management LP raised its holdings in shares of Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after purchasing an additional 1,471,631 shares during the period. Finally, Counterpoint Mutual Funds LLC raised its holdings in shares of Teladoc Health by 1,017.4% during the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock valued at $9,571,000 after purchasing an additional 1,502,488 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. Barclays increased their target price on shares of Teladoc Health from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 4th. Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Needham & Company LLC reiterated a “hold” rating on shares of Teladoc Health in a research report on Thursday, October 29th. JPMorgan Chase & Co. lifted their target price on shares of Teladoc Health from $8.00 to $10.00 and gave the stock a “neutral” rating in a research note on Friday, October 30th. Finally, Truist Financial dropped their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.53.
Get Our Latest Stock Report on TDOC
Teladoc Health Company Profile
Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.
Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.
Read More
- Five stocks we like better than Teladoc Health
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
